Prostate Cancer: Radiation therapy
暂无分享,去创建一个
[1] Yoshiya Yamada,et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. , 2008, International journal of radiation oncology, biology, physics.
[2] Y. Yamada,et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[3] Charles R. Thomas,et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.
[4] Ming-Hui Chen,et al. Magnetic resonance image‐guided salvage brachytherapy after radiation in select men who initially presented with favorable‐risk prostate cancer , 2007, Cancer.
[5] A. D'Amico,et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate‐specific antigen failure , 2007, Cancer.
[6] F. Mottaghy,et al. Evaluation of [11C]‐choline positron‐emission/computed tomography in patients with increasing prostate‐specific antigen levels after primary treatment for prostate cancer , 2007, BJU international.
[7] H. Hricak,et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. , 2007, International journal of radiation oncology, biology, physics.
[8] Christopher A Peters,et al. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. , 2007, International journal of radiation oncology, biology, physics.
[9] Peter Bownes,et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] K. Wallner,et al. Long‐term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high‐risk features , 2007, Cancer.
[11] M. Kattan,et al. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. , 2007, Urology.
[12] G. Pond,et al. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. , 2007, Brachytherapy.
[13] A. Su,et al. Chronic Genitourinary and Gastrointestinal Toxicity of Prostate Cancer Patients Undergoing Pelvic Radiotherapy With Intensity-Modulated Versus 4-Field Technique , 2007, American journal of clinical oncology.
[14] M. Parmar,et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.
[15] W. van Putten,et al. Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. , 2007, International journal of radiation oncology, biology, physics.
[16] H. Zaidi,et al. 18F‐choline and/or 11C‐acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate‐specific antigen values (<1 ng/mL) after radical prostatectomy , 2007, BJU international.
[17] E. Messing,et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Shah,et al. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation. , 2007, Urology.
[19] L. Kestin,et al. Use of Individual Fraction Size Data from 3756 Patients to Directly Determine the α/β Ratio of Prostate Cancer , 2007 .
[20] S. Tyldesley,et al. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. , 2007, International journal of radiation oncology, biology, physics.
[21] J. Pouliot,et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. , 2007, International journal of radiation oncology, biology, physics.
[22] Louis Potters,et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. , 2007, International journal of radiation oncology, biology, physics.
[23] R. Stock,et al. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.
[24] Moyed Miften,et al. Patient dose and image quality from mega-voltage cone beam computed tomography imaging. , 2007, Medical physics.
[25] D. Theodorescu,et al. Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. , 2006, International journal of radiation oncology, biology, physics.
[26] E. Messing,et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.
[27] R. Holloway,et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. , 2006, International journal of radiation oncology, biology, physics.
[28] Neal Goldstein,et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. , 2006, International journal of radiation oncology, biology, physics.
[29] Yoshiya Yamada,et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. , 2006, The Journal of urology.
[30] J. Crook,et al. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Steve Webb,et al. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[32] M. Heckman,et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. , 2006, The Journal of urology.
[33] Michael W Kattan,et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Damber,et al. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. , 2006, The Journal of urology.
[35] Paul Schellhammer,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.
[36] Marco Zaider,et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. , 2006, Brachytherapy.
[37] M. Kattan,et al. Nomograms for prostate cancer , 2006, BJU international.
[38] Evis Sala,et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. , 2006, Radiology.
[39] Joos V Lebesque,et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] T. Wilt,et al. Neo‐adjuvant and adjuvant hormone therapy for localised prostate cancer , 2006 .
[41] H. Hricak,et al. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. , 2006, Radiology.
[42] A. Renshaw,et al. Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .
[43] Patrick A Kupelian,et al. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. , 2005, International journal of radiation oncology, biology, physics.
[44] A. Pollack,et al. Parameters for treatment decisions for salvage radiation therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] A. D'Amico,et al. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] C. D’Este,et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. , 2005, The Lancet. Oncology.
[47] Barry S Rosenstein,et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.
[48] R. Stock,et al. Salvage Prostate Brachytherapy Following Radiotherapy Failure , 2005 .
[49] Daniel W. Miller,et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.
[50] J. Brooks,et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] M. Piérart,et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.
[52] Patrick A Kupelian,et al. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. , 2005, International journal of radiation oncology, biology, physics.
[53] J. Mulhall,et al. The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations. , 2005, The Journal of urology.
[54] P. Scardino,et al. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. , 2005, International journal of radiation oncology, biology, physics.
[55] Wayne M Butler,et al. Erectile function after prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.
[56] Leen Paelinck,et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[57] J. Fowler,et al. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy , 2005, Acta oncologica.
[58] A. Hanlon,et al. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. , 2005, International journal of radiation oncology, biology, physics.
[59] D. Grignon,et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.
[60] Caitlin Gillan,et al. Posttreatment Complications of Early‐Stage Prostate Cancer Patients: Brachytherapy Versus Three‐Dimensional Conformal Radiation Therapy , 2005, Cancer journal.
[61] R. Stock,et al. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. , 2005, The Journal of urology.
[62] M. Kattan,et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.
[63] Qing Guo,et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Ping Xia,et al. Low-dose megavoltage cone-beam CT for radiation therapy. , 2005, International journal of radiation oncology, biology, physics.
[65] F. Critz,et al. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. , 2004, The Journal of urology.
[66] E. B. Butler,et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. , 2004, JAMA.
[67] J. Manola,et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.
[68] R. Stock,et al. Combined modality treatment in the management of high-risk prostate cancer. , 2004, International journal of radiation oncology, biology, physics.
[69] Ming-Hui Chen,et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.
[70] M. Regan,et al. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. , 2004, The Journal of urology.
[71] D. Baltas,et al. 3-D Conformal HDR Brachytherapy as Monotherapy for Localized Prostate Cancer , 2004, Strahlentherapie und Onkologie.
[72] T. Mate,et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.
[73] G. Gustafson,et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. , 2004, The Journal of urology.
[74] A. Fortin,et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. , 2004, The Journal of urology.
[75] W. Cavanagh,et al. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. , 2003, International journal of radiation oncology, biology, physics.
[76] J. Blasko,et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. , 2003, International journal of radiation oncology, biology, physics.
[77] R. Stock,et al. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. , 2003, International journal of radiation oncology, biology, physics.
[78] D. Grignon,et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] W. J. Morris,et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] M. Cooperberg,et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. , 2003, Journal of the National Cancer Institute.
[81] V. Nitti,et al. American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life. , 2003, Urology.
[82] F. Hamdy,et al. Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. , 2003, Controlled clinical trials.
[83] R K Valicenti,et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] R. Galalae,et al. Fractionated perineal high-dose-rate temporary brachytherapy combined with external beam radiation in the treatment of localized prostate cancer: is lymph node sampling necessary? , 2003, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[85] Adam P Dicker,et al. Probability of late rectal morbidity in 125I prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.
[86] Marco Zaider,et al. Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning. , 2002, International journal of radiation oncology, biology, physics.
[87] L. Potters,et al. Clinical investigation: prostateRadical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer , 2004 .
[88] C. Reddy,et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] J. Wong,et al. Flat-panel cone-beam computed tomography for image-guided radiation therapy. , 2002, International journal of radiation oncology, biology, physics.
[90] George Starkschall,et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.
[91] Jacques Bernier,et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.
[92] A W Partin,et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.
[93] A. Sethi,et al. Radiation exposure to the corporeal bodies during 3-dimensional conformal radiation therapy for prostate cancer. , 2002, The Journal of urology.
[94] C. Catton,et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. , 2002, International journal of radiation oncology, biology, physics.
[95] Michael W Kattan,et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.
[96] K. Wallner,et al. Dosimetric and radiographic correlates to prostate brachytherapy‐related rectal complications , 2001, International journal of cancer.
[97] Cedric Yu,et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. , 2001, International journal of radiation oncology, biology, physics.
[98] F. Vicini,et al. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. , 2001, The Journal of urology.
[99] J. Cherlow,et al. High-dose-rate brachytherapy in the treatment of carcinoma of the prostate. , 2001, Cancer control : journal of the Moffitt Cancer Center.
[100] C C Ling,et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.
[101] J. Blasko,et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. , 2001, Urology.
[102] D. Grignon,et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.
[103] C. Reddy,et al. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10). , 2001, International journal of radiation oncology, biology, physics.
[104] P. O'Brien,et al. Radiation injury of the rectum. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[105] A. Romagnoli,et al. Roach's Mathematical Equations in Predicting Pathological Stage in Men with Clinically Localized Prostate Cancer , 2001, Tumori.
[106] A. Renshaw,et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. , 2001, International journal of radiation oncology, biology, physics.
[107] N Lee,et al. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.
[108] J. Manola,et al. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.
[109] P. Grimm,et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. , 1999, International journal of radiation oncology, biology, physics.
[110] S. Turner,et al. Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. , 1999, Urology.
[111] A. Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[112] J. Chin,et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. , 1999, Urology.
[113] R. Stock,et al. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. , 1998, The Journal of urology.
[114] A. Renshaw,et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, JAMA.
[115] T E Schultheiss,et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. , 1998, International journal of radiation oncology, biology, physics.
[116] M. Kattan,et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.
[117] R. Stock,et al. A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.
[118] A. Zietman,et al. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. , 1997, International journal of radiation oncology, biology, physics.
[119] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[120] M. Zelefsky,et al. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. , 1997, Urology.
[121] L. Verhey,et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. , 1995, International journal of radiation oncology, biology, physics.
[122] C. Perez,et al. Technical and tumor-related factors affecting outcome of definitive irradiation for localized carcinoma of the prostate. , 1993, International journal of radiation oncology, biology, physics.
[123] T. Phan,et al. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. , 2007, The Journal of urology.
[124] Mark J Rivard,et al. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. , 2007, Brachytherapy.
[125] G. Gagnon,et al. Combined external beam radiotherapy and Pd‐103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: Results of a matched pair analysis , 2005, The Prostate.
[126] G. Gustafson,et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. , 2001, International journal of radiation oncology, biology, physics.
[127] R. Stock,et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.
[128] M. Zelefsky,et al. Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection. , 2000, International journal of radiation oncology, biology, physics.
[129] L. Potters,et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. , 1999, International journal of radiation oncology, biology, physics.
[130] M. Zelefsky,et al. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. , 1998, International journal of radiation oncology, biology, physics.
[131] G E Hanks,et al. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[132] P. Carroll,et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.
[133] B Pickett,et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.
[134] J. Hopewell,et al. Microvasculature and radiation damage. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.